Pfizer (PFE) Stock Forecast & Price Target

Compare

35,658 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PFE Analyst Ratings

Hold

4 Buy

11 Hold

1 Sell

Based on 16 analysts giving stock ratings to

Pfizer

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PFE Stock 12 Month Forecast

Average Price Target

$28.92

▲(14.44% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $28.92 with a high forecast of $35.00 and a low forecast of $24.00. The average price target represents a 14.44% change from the last price of $25.27.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","36":"$36","24.75":"$24.8","28.5":"$28.5","32.25":"$32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,24.75,28.5,32.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.27,26.018461538461537,26.766923076923078,27.515384615384615,28.263846153846153,29.012307692307694,29.76076923076923,30.50923076923077,31.25769230769231,32.00615384615384,32.754615384615384,33.503076923076925,34.25153846153846,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.27,25.55076923076923,25.83153846153846,26.11230769230769,26.393076923076922,26.673846153846153,26.954615384615387,27.235384615384618,27.51615384615385,27.79692307692308,28.07769230769231,28.35846153846154,28.63923076923077,{"y":28.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.27,25.17230769230769,25.074615384615385,24.976923076923075,24.87923076923077,24.78153846153846,24.683846153846154,24.586153846153845,24.48846153846154,24.39076923076923,24.293076923076924,24.195384615384615,24.097692307692306,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$28.92

Lowest Price Target$24.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geoff Meacham

Citi

$26

Hold

2.89%

Upside

Initiated

12/02/25

Pfizer's Balanced Outlook: Strong Performance Amidst Upcoming Challenges and Strategic Opportunities

Courtney Breen

Bernstein

―

Hold

―

Reiterated

12/02/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), Pfizer (NYSE: PFE) and Janux Therapeutics Inc (NASDAQ: JANX)We rate MRK, PFE, MRNA as market perform.

Kerry Holford

Berenberg Bank

$25

Hold

-1.07%

Downside

Reiterated

11/26/25

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)

Mohit Bansal

Wells Fargo

$28

Hold

10.80%

Upside

Reiterated

11/25/25

Pfizer (PFE) Gets a Hold from Wells Fargo

Vamil Divan

Guggenheim

$33→$35

Buy

38.50%

Upside

Reiterated

11/23/25

Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Adagene (ADAG)

Evan Seigerman

BMO Capital

$30

Buy

18.72%

Upside

Reiterated

11/13/25

Analysts' Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE)

Louise Chen

Scotiabank

$30

Buy

18.72%

Upside

Initiated

11/12/25

Pfizer initiated with an Outperform at ScotiabankPfizer initiated with an Outperform at Scotiabank

Terence Flynn

Morgan Stanley

$32

Hold

26.63%

Upside

Reiterated

11/10/25

Cautious Optimism: Pfizer's Strategic Initiatives and Clinical Trials Amidst Oncology Competition

Chris Schott

J.P. Morgan

―

Hold

―

Reiterated

11/09/25

Pfizer's Strategic Acquisition of Metsera: Balancing Opportunities and Risks in the Obesity Market

Akash Tewari

Jefferies

$34

Buy

34.55%

Upside

Reiterated

11/05/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Steve Scala

TD Cowen

$30

Hold

18.72%

Upside

Reiterated

11/04/25

Pfizer (PFE) Receives a Hold from TD Cowen

Carter Gould

Cantor Fitzgerald

$24

Hold

-5.03%

Downside

Reiterated

11/04/25

Pfizer (PFE) Gets a Hold from Cantor Fitzgerald

Tim Anderson

Bank of America Securities

$28→$30

Hold

18.72%

Upside

Reiterated

10/22/25

Pfizer's Growth Outlook: Hold Rating Amid Declining Revenue and Uncertain Prospects

David Risinger

Leerink Partners

―

Hold

―

Reiterated

09/23/25

Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)

Asad Haider

Goldman Sachs

$27

Hold

6.85%

Upside

Reiterated

09/22/25

Goldman Sachs Sticks to Its Hold Rating for Pfizer (PFE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geoff Meacham

Citi

$26

Hold

2.89%

Upside

Initiated

12/02/25

Pfizer's Balanced Outlook: Strong Performance Amidst Upcoming Challenges and Strategic Opportunities

Courtney Breen

Bernstein

―

Hold

―

Reiterated

12/02/25

Kerry Holford

Berenberg Bank

$25

Hold

-1.07%

Downside

Reiterated

11/26/25

Berenberg Bank Reaffirms Their Hold Rating on Pfizer (PFE)

Mohit Bansal

Wells Fargo

$28

Hold

10.80%

Upside

Reiterated

11/25/25

Pfizer (PFE) Gets a Hold from Wells Fargo

Vamil Divan

Guggenheim

$33→$35

Buy

38.50%

Upside

Reiterated

11/23/25

Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Adagene (ADAG)

Evan Seigerman

BMO Capital

$30

Buy

18.72%

Upside

Reiterated

11/13/25

Analysts' Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE)

Louise Chen

Scotiabank

$30

Buy

18.72%

Upside

Initiated

11/12/25

Pfizer initiated with an Outperform at ScotiabankPfizer initiated with an Outperform at Scotiabank

Terence Flynn

Morgan Stanley

$32

Hold

26.63%

Upside

Reiterated

11/10/25

Cautious Optimism: Pfizer's Strategic Initiatives and Clinical Trials Amidst Oncology Competition

Chris Schott

J.P. Morgan

―

Hold

―

Reiterated

11/09/25

Pfizer's Strategic Acquisition of Metsera: Balancing Opportunities and Risks in the Obesity Market

Akash Tewari

Jefferies

$34

Buy

34.55%

Upside

Reiterated

11/05/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Steve Scala

TD Cowen

$30

Hold

18.72%

Upside

Reiterated

11/04/25

Pfizer (PFE) Receives a Hold from TD Cowen

Carter Gould

Cantor Fitzgerald

$24

Hold

-5.03%

Downside

Reiterated

11/04/25

Pfizer (PFE) Gets a Hold from Cantor Fitzgerald

Tim Anderson

Bank of America Securities

$28→$30

Hold

18.72%

Upside

Reiterated

10/22/25

Pfizer's Growth Outlook: Hold Rating Amid Declining Revenue and Uncertain Prospects

David Risinger

Leerink Partners

―

Hold

―

Reiterated

09/23/25

Leerink Partners Keeps Their Hold Rating on Pfizer (PFE)

Asad Haider

Goldman Sachs

$27

Hold

6.85%

Upside

Reiterated

09/22/25

Goldman Sachs Sticks to Its Hold Rating for Pfizer (PFE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

1 Month

xxx

Success Rate

16/30 ratings generated profit

Average Return

-0.09%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -0.09% per trade.

3 Months

xxx

Success Rate

23/35 ratings generated profit

Average Return

+2.40%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.71% of your transactions generating a profit, with an average return of +2.40% per trade.

1 Year

Vamil DivanGuggenheim

Success Rate

25/35 ratings generated profit

Average Return

+4.71%

reiterated a buy rating 11 days ago

Copying Vamil Divan's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +4.71% per trade.

2 Years

xxx

Success Rate

25/35 ratings generated profit

Average Return

+7.17%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +7.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PFE Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PFE has received 13 Buy Ratings, 23 Hold Ratings, and 0 Sell Ratings. PFE average Analyst price target in the past 3 months is 28.92.

Each month's total comprises the sum of three months' worth of ratings.

PFE Financial Forecast

PFE Earnings Forecast

Next quarter’s earnings estimate for PFE is $0.60 with a range of $0.44 to $0.77. The previous quarter’s EPS was $0.87. PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.

PFE Sales Forecast

Next quarter’s sales forecast for PFE is $17.47B with a range of $15.98B to $18.93B. The previous quarter’s sales results were $16.65B. PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PFE has Performed in-line its overall industry.

PFE Stock Forecast FAQ

What is PFE’s average 12-month price target, according to analysts?

Based on analyst ratings, Pfizer’s 12-month average price target is 28.92.

What is PFE’s upside potential, based on the analysts’ average price target?

Pfizer has 14.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PFE a Buy, Sell or Hold?

Pfizer has a consensus rating of Hold which is based on 4 buy ratings, 11 hold ratings and 1 sell ratings.

What is Pfizer’s price target?

The average price target for Pfizer is 28.92. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $24.00. The average price target represents 14.44% Increase from the current price of $25.27.

What do analysts say about Pfizer?

Pfizer’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of PFE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Pfizer (PFE) Stock Forecast & Price Target

PFE Analyst Ratings

PFE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pfizer

PFE Analyst Recommendation Trends

PFE Financial Forecast

PFE Earnings Forecast

PFE Sales Forecast

PFE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts